Silibinin inhibits the production of pro-inflammatory cytokines through inhibition of NF-κB signaling pathway in HMC-1 human mast cells

Inflammation Research

Volumn 62, Issue 11, 2013, Pages 941-950

  Kim, Beom Rak ^a   Seo, Hye Sook ^b   Ku, Jin Mo ^b   Kim, Gyung Jun ^a   Jeon, Chan Yong ^a   Park, Jong Hyeong ^a   Jang, Bo Hyoung ^b   Park, Sun Ju ^b   Shin, Yong Cheol ^b   Ko, Seong Gyu ^b  

^a Gachon University College of Medicine   (South Korea)

^b Kyung Hee University   (South Korea)

Author keywords

Allergic inflammation; Cirsium japonicum; Human mast cells; NF B; Pro inflammatory cytokine; Silibinin

Indexed keywords

HISTAMINE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; SILIBININ; TUMOR NECROSIS FACTOR ALPHA;

ALLERGY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL GROWTH; CELL NUCLEUS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG STRUCTURE; GROWTH INHIBITION; HISTAMINE RELEASE; HUMAN; HUMAN CELL; MAST CELL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-ALLERGIC AGENTS; CELL LINE; CELL SURVIVAL; CYTOKINES; HUMANS; I-KAPPA B KINASE; MAST CELLS; MICE; NF-KAPPA B; RNA, MESSENGER; SILYMARIN;

EID: 84888201594     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-013-0640-1     Document Type: Article

References (35)

1. Ferrero-Miliani L, Nielsen OH, Andersen PS, Girardin SE. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation. Clin Exp Immunol. 2007;2007(147):227-35.
2. Rosenwasser LJ. Current understanding of the pathophysiology of allergic rhinitis. Immunol Allergy Clin North Am. 2011;31:433-9.
3. Rose S, Weld-Moore R, Ghazali N, Newman L. I've got hay-fever and my mouth is stinging! Br Dent J. 2011;211:369-70.
4. Olivera A, Rivera J. An emerging role for the lipid mediator sphingosine-1-phosphate in mast cell effector function and allergic disease. Adv Exp Med Biol. 2011;716:123-42.
5. Kuna P, Reddigari SR, Rucinski D, Oppenheim JJ, Kaplan AP. Monocyte chemotactic and activating factor is a potent histamine-releasing factor for human basophils. J Exp Med. 1992;175:489-93.
6. Wang SL, Malany S, Wang Q, Santos MA, Crowe PD, Maki RA. Histamine induces interleukin-6 expression in the human synovial sarcoma cell line (SW982) through the H1 receptor. Inflamm Res. 2006;55:393-8.
7. Thomas PS. Tumor necrosis factor-alpha: the role of this multifunctional cytokine in asthma. Immunol Cell Biol. 2001;79:132-40.
8. Naka S, Suto H, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cells enhance T cell activation: importance of mast cell-derived TNF. Proc Natl Acad Sci USA. 2005;10:6467-72.
9. Bodreau RT, Hoskin DW, Lin TJ. Phosphatase inhibition potentiates IL-6 production by mast cells in response to FcεRI-mediated activation: involvement of p38 MAPK. J Leukoc Biol. 2004;76:1075-81.
10. Murayama T, Mukaida N, Sadanari H, Yamaguchi N, Khabar KS, Tanaka J, Matsushima K, Mori S, Eizuru Y. The immediate early gene 1 product of human cytomegalovirus is sufficient for up-regulation of interleukin-8 gene expression. Biochem Biophys Res Commun. 2000;279:298-304.
11. Kuprsh DV, Udalova IA, Turetskaya RL, Rice NR, Nedospasov SA. Conserved kappa B element located downstream of the tumor necrosis factor alpha gene: distinct NF-kappa B binding pattern and enhancer activity in LPS activated murine macrophages. Oncogene. 1995;11:97-106.
12. Galien R, Evans HF, Garcia T. Involvement of CCAAT/enhancer-binding protein and nuclear factor-kappa B binding site in interleukin-6 promoter inhibition by estrogens. Mol Endocrinol. 1996;10:713-22.
13. Kim DY, Kang SH, Ghil SH. Cirsium japonicum extract induces apoptosis and anti-proliferation in the human breast cancer cell line MCF-7. Mol Med Rep. 2010;3:427-32.
14. Ishida H, Umino T, Tsuji K, Kosuge T. Studies on antihemorrhagic substances in herbs classified as hemostatics in Chinese medicine. VII. On the antihemorrhagic principle in Cirsium japonicum DC. Chem Pharm Bull. 1987;35:861-4.
15. Park MK, Rhyu MR, Yoon BK, Kwon H, Jang S, Lee YJ. Modulation of the genomic estrogen receptor pathway by water extracts of Cirsium japonicum. Arch Pharm Res. 2008;31:225-30.
16. Kim EY, Jho HK, Kim DI, Rhyu MR. Cirsium japonicum elicits endothelium-dependent relaxation via histamine H(1)-receptor in rat thoracic aorta. J Ethnopharmacol. 2008;116:223-7.
17. Yin J, Heo SI, Wang MH. Antioxidant and antidiabetic activities of extracts from Cirsium japonicum roots. Nutr Res Pract. 2008;2:247-51.
18. Liu SJ, Luo X, Li DX, Zhang J, Qiu DL, Liu W, She L, Yang ZR. Tumor inhibition and improved immunity in mice treated with flavone from Cirsium japonicum DC. Int Immunopharmacol. 2006;6:1387-93.
19. Schumann J, Prockl J, Kiemer AK, Vollmar AM, Bang R, Tiegs G. Silibinin protects mice from T cell-dependent liver injury. J Hepatol. 2003;39:333-40.
20. Wu JW, Lin LC, Hung SC, Lin CH, Chi CW, Tsai TH. Hepatobiliary excretion of silibinin in normal and liver cirrhotic rats. Drug Metab Dispos. 2008;36:589-96.
21. Gazák R, Walterová D, Kren V. Silybin and silymarin - new and emerging applications in medicine. Curr Med Chem. 2007;14:315-38.
22. Duan W, Jin X, Li Q, Tashiro S, Onodera S, Ikejima T. Silibinin induced autophagic and apoptotic cell death in HT1080 cells through a reactive oxygen species pathway. J Pharmacol Sci. 2010;113:48-56.
23. Hoh C, Boocock D, Marczylo T, Singh R, Berry DP, Dennison AR, Hemingway D, Miller A, West K, Euden S, Garcea G, Farmer PB, Steward WP, Gescher AJ. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin Cancer Res. 2006;12:2944-50.
24. Sharma G, Singh RP, Chan DC, Agarwal R. Silibinin induces growth inhibition and apoptotic cell death in human lung carcinoma cells. Anticancer Res. 2003;23:2649-55.
25. Bang CI, Paik SY, Sun DI, Joo YH, Kim MS. Cell growth inhibition and down-regulation of survivin by silibinin in a laryngeal squamous cell carcinoma cell line. Ann Otol Rhinol Laryngol. 2008;117:781-5.
26. Choi YH, Yan GH. Silibinin attenuates mast cell-mediated anaphylaxis-like reactions. Biol Pharm Bull. 2009;32:868-75.
27. Harada M, Nagata M, Takeuchi M. Production of passive cutaneous anaphylaxis (PCA) and reversed PCA by rat IgE antibody in the mouse. Experientia. 1988;44:459-62.
28. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol. 2002;2:446-53.
29. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454:445-54.
30. Bischoff SC. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat Rev Immunol. 2007;7:93-104.
31. Lippert U, Moller A, Welker P, Artuc M, Henz BM. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol. 2000;9:118-24.
32. Cruse G, Kaur D, Yang W, Duffy SM, Brightling CE, Bradding P. Activation of human lung mast cells by monomeric immunoglobulin E. Eur Respir J. 2005;25:858-63.
33. Choi IW, Kim YS, Kim DK, Choi JH, Seo KH, Im SY, Kwon KS, Lee MS, Ha TY, Lee HK. Platelet-activating factor-mediated NF-kappaB dependency of a late anaphylactic reaction. J Exp Med. 2003;198:145-51.
34. Mohamed MR, McFadden G. NFκB inhibitors: strategies from poxviruses. Cell Cycle. 2009;8:3125-32.
35. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1:135-45.